OFF-LABEL USE OF ANTICANCER DRUGS: WHICH BENEFITS AND HOW MUCH?
PS-029
MEDICATION NON-ADHERENCE IN ELDERLY PATIENTS
PS-028
ELECTRONIC PRESCRIBING SYSTEMS IN OUTPATIENT CARE. SOURCE OF INFORMATION OR SOURCE OF ERRORS?
PS-026
DATA MINING: PHARMACOVIGILANCE SIGNAL OF BENZODIAZEPINES AND SKIN AND SUBCUTANEOUS TISSUE DISORDERS
PS-025
ANALYSIS OF THE UTILISATION OF ZOLPIDEM IN HOSPITALISED PATIENTS
PS-024
MEDICATION DISCREPANCIES AT THE TRANSFER POINT FROM ICU TO WARD: NEED TO BRIDGE SOME GAPS
PS-023
AROMATASE INHIBITORS INDUCED CARPAL TUNNEL SYNDROME. A CASE/NON-CASE STUDY OF SUSPECTED ADVERSE DRUG REACTIONS IN VIGIBASE
PS-021
PRESCRIPTION ERRORS IN ORAL INVESTIGATIONAL PRODUCTS FOR ONCOHAEMATOLOGIC OUTPATIENTS INCLUDED IN A CLINICAL TRIAL
PS-019
CONCOMITANT USE OF DRUGS WITH ANTICHOLINERGIC EFFECTS AND ACETYLCHOLINESTERASE INHIBITORS IN ELDERLY PEOPLE WITH COGNITIVE IMPAIRMENT IN A NURSING HOME
PS-017
QUALITY AND RISK MANAGEMENT IN HOSPITALS: AUDIT OF SURGICAL ANTIBIOTIC PROPHYLAXIS
PS-016
PERCEPTIONS OF POTENTIAL ANTIBIOTIC PRESCRIBING BY PHARMACISTS
PS-015
E-LEARNING TO REDUCE INTRAVENOUS MEDICATION ERRORS? SIMULATION STUDY IN A ‘ROOM OF ERRORS’
PS-014
SAFETY ANALYSIS OF LEDIPASVIR/SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: ADVERSE EVENTS AND DRUG INTERACTIONS
PS-013
SAFETY PROGRAMME TO AVOID SKIN BURNS ASSOCIATED WITH TRANSDERMAL PATCHES
PS-012
IMPLEMENTATION OF A SUPPORT PROGRAMME FOR ANTIMICROBIAL PRESCRIPTION: A 3 MONTH EXPERIENCE
